BioPharma Resources

Drug Trial Radar · NCT04424316

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 14,727 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

14,727

Actual

Start

Jun 17, 2020

Primary completion

Oct 27, 2023

Study completion Oct 27, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 0 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

Conditions

  • Respiratory Tract Infection

Interventions

  • RSVpreFBiological

    RSV vaccine (RSVpreF)

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)Time frame: Within 90 days after birth
  2. Percentage of Infant Participants With MA-LRTI Cases Due to RSV Occurring Within 120 Days After Birth (Efficacy)Time frame: Within 120 days after birth
  3. Percentage of Infant Participants With MA-LRTI Cases Due to RSV Occurring Within 150 Days After Birth (Efficacy)Time frame: Within 150 days after birth
  4. Percentage of Infant Participants With MA-LRTI Cases Due to RSV Occurring Within 180 Days After Birth (Efficacy)Time frame: Within 180 days after birth
  5. Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)Time frame: Within 90 days after birth
  6. Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 120 Days After Birth (Efficacy)Time frame: Within 120 days after birth
  7. Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 150 Days After Birth (Efficacy)Time frame: Within 150 days after birth
  8. Percentage of Infant Participants With Severe MA-LRTI Cases Due to RSV Occurring Within 180 Days After Birth (Efficacy)Time frame: Within 180 days after birth
  9. Percentage of Infant Participants With Adverse Events of Special Interest (AESI) (Safety)Time frame: From birth to 24 months of age
  10. Percentage of Infant Participants With Neonatal Deaths (Safety)Time frame: Within 1 Month after birth
  11. Percentage of Infant Participants With Congenital Malformations/Anomalies (Safety)Time frame: At birth
  12. Percentage of Infant Participants With Other Neonatal Events (Safety)Time frame: Within 1 Month after birth
  13. Number of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth (Safety)Time frame: 1 minute after birth
  14. Number of Infant Participants According to APGAR Score at 5 Minutes After Birth (Safety)Time frame: 5 minutes after birth
  15. Number of Infant Participants According to APGAR Score at 10 Minutes After Birth (Safety)Time frame: 10 minutes after birth
  16. Percentage of Infant Participants With Adverse Events (AEs) From Birth to 1 Month of Age (Safety)Time frame: From birth to 1 month of age
  17. Percentage of Infant Participants With Serious Adverse Events (SAEs) and Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age (Safety)Time frame: From birth to 6 months of age
  18. Percentage of Infant Participants With SAEs and NDCMCs From Birth Through 12 Months of Age (Safety)Time frame: From birth to 12 months of age
  19. Percentage of Infant Participants With SAEs and NDCMCs From Birth Through 24 Months of Age (Safety)Time frame: From birth to 24 months of age
  20. Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination (Safety)Time frame: From Day 1 to Day 7 after vaccination
  21. Percentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination (Safety)Time frame: From Day 1 to Day 7 after vaccination
  22. Percentage of Maternal Participants With AEs From the Time of Vaccination Through 1 Month After Vaccination (Safety)Time frame: From vaccination on Day 1 up to 1 month after vaccination
  23. Percentage of Maternal Participants With SAEs Throughout the Study Period (Safety)Time frame: From vaccination on Day 1 up to 6 months after delivery (maximum up to 10 months)

Locations

464 sites in 18 countries. Site status is shown where the registry gives one.

  • Central Research Associates, Inc.

    Birmingham, Alabama

  • Endocrinology and Internal Medicine Associates, PC

    Birmingham, Alabama

  • OB/GYN Associates of Alabama, PC

    Birmingham, Alabama

  • Sharp and Stone OB/GYN PC

    Birmingham, Alabama

  • St Vincent's Hospital

    Birmingham, Alabama

  • Children's of Alabama

    Birmingham, Alabama

  • UAB Women & Infants Center - UAB Medicine

    Birmingham, Alabama

  • University of Alabama at Birmingham/Center for Women's Reproductive Health

    Birmingham, Alabama

  • Cullman Clinical Research, Inc

    Cullman, Alabama

  • Cullman Primary Care, PC

    Cullman, Alabama

  • Cullman Regional

    Cullman, Alabama

  • University of South Alabama Children's and Women's Hospital

    Mobile, Alabama

  • USA Health Strada Patient Care Center

    Mobile, Alabama

  • Springhill Medical Center

    Mobile, Alabama

  • Velocity Clinical Research, Gulfport

    Mobile, Alabama

  • Velocity Clinical Research - Pheonix

    Phoenix, Arizona

  • Valleywise Comprehensive Health Center Women's Clinic

    Phoenix, Arizona

  • Valleywise Health Medical Center

    Phoenix, Arizona

  • Mesquite Pediatrics

    Tucson, Arizona

  • Watching Over Mothers and Babies

    Tucson, Arizona

  • Banner University Medical Center

    Tucson, Arizona

  • University of Arizona

    Tucson, Arizona

  • Banner University Medical Center ( North Campus )

    Tucson, Arizona

  • St. Bernards Medical Center

    Jonesboro, Arkansas

  • St. Bernards OBGYN Associates

    Jonesboro, Arkansas

  • The Children's Clinic of Jonesboro, P.A.

    Jonesboro, Arkansas

  • The Children's Clinic of Jonesboro, PA

    Jonesboro, Arkansas

  • Century Research Institute

    Bellflower, California

  • Chowchilla Medical Center

    Chowchilla, California

  • Loma Linda University Pediatric Clinic - Highland

    Highland, California

  • Century Research Institute

    Huntington Park, California

  • Matrix Clinical Research

    Huntington Park, California

  • Chemidox Clinical Trials

    Lancaster, California

  • Leonard S. Kurian, M.D., A Medical Corporation

    Lancaster, California

  • Women & Infants Pavilion, Antelope Valley Hospital

    Lancaster, California

  • Loma Linda University Adventist Health Sciences Center

    Loma Linda, California

  • Loma Linda University Faculty Medical Clinics

    Loma Linda, California

  • Loma Linda University Pediatric Clinics

    Loma Linda, California

  • Loma Linda Unversity Children's Hospital

    Loma Linda, California

  • Long Beach Clinical Trials

    Long Beach, California

Showing 40 of 464 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.